Stock MYMD MYMD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
1.94 USD -0.77% Intraday chart for MyMD Pharmaceuticals, Inc. -11.42% -75.00%
06-17 MyMD Pharmaceuticals Announces Executive Appointments CI
05-23 MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc. CI

Business Summary

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Number of employees: 6

Managers

Managers TitleAgeSince
Ian Rhodes DFI
 Director of Finance/CFO 51 21-04-14
Christopher Schreiber BRD
 Director/Board Member 58 17-08-07
Robert Schatz IRC
 Investor Relations Contact - -
Jenna Brager LAW
 General Counsel - 21-04-30

Members of the board

Members of the board TitleAgeSince
Christopher Schreiber BRD
 Director/Board Member 58 17-08-07
Joshua Silverman CHM
 Chairman 54 18-09-05
Bill White BRD
 Director/Board Member 63 17-08-07
Craig Eagle BRD
 Director/Board Member 57 21-04-15
Jude Uzonwanne BRD
 Director/Board Member 50 21-04-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 9,859 0 0 93.15 %
Stock B 0 72,992 0 0
Stock C 1 2,307,632 2,149,627 ( 93.15 %) 0

Shareholders

NameEquities%Valuation
Global X Management Co. LLC
37.96 %
875,933 37.96 % 2 M $
Caroline C Williams
5.409 %
124,815 5.409 % 232 156 $
Richard Abbe
1.334 %
30,791 1.334 % 57 271 $
Vanguard Global Advisers LLC
1.329 %
30,657 1.329 % 57 022 $
Paul Rivard
0.5778 %
13,334 0.5778 % 24 801 $
BlackRock Institutional Trust Co. NA
0.2841 %
6,555 0.2841 % 12 192 $
Iroquois Capital Management LLC
0.2707 %
6,247 0.2707 % 11 619 $
Joshua Silverman
0.2167 %
5,000 0.2167 % 9 300 $
Premas Biotech Pvt Ltd.
0.1499 %
3,459 0.1499 % 6 434 $
UBS Securities LLC
0.0847 %
1,955 0.0847 % 3 636 $
NameEquities%Valuation
Iroquois Capital Management LLC
13.89 %
2,083 13.89 % 3 874 $
NameEquities%Valuation
Premas Biotech Pvt Ltd.
34.54 %
72,992 34.54 % 135 765 $

Company contact information

MyMD Pharmaceuticals, Inc.

855 North Wolfe Street Suite 601

21205, Baltimore

+

http://www.mymd.com
address MyMD Pharmaceuticals, Inc.(MYMD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MYMD PHARMACEUTICALS, INC. Stock MyMD Pharmaceuticals, Inc.
-75.00% 4.48M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.19% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.91% 114B
ARGENX SE Stock argenx SE
+18.34% 23.61B
BIONTECH SE Stock BioNTech SE
-19.80% 20.43B
GENMAB A/S Stock Genmab A/S
-15.68% 16.55B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.45% 16.45B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.59B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+66.67% 15.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.13% 13.54B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MYMD Stock
  4. Company MyMD Pharmaceuticals, Inc.